1. Home
  2. JOB vs TPST Comparison

JOB vs TPST Comparison

Compare JOB & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GEE Group Inc.

JOB

GEE Group Inc.

HOLD

Current Price

$0.21

Market Cap

25.2M

ML Signal

HOLD

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$1.05

Market Cap

26.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JOB
TPST
Founded
1893
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.2M
26.2M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
JOB
TPST
Price
$0.21
$1.05
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$11.00
AVG Volume (30 Days)
150.1K
99.7K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$96,504,000.00
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$1.02
52 Week High
$0.28
$12.22

Technical Indicators

Market Signals
Indicator
JOB
TPST
Relative Strength Index (RSI) 36.41 22.57
Support Level $0.19 N/A
Resistance Level $0.21 $2.48
Average True Range (ATR) 0.01 0.07
MACD -0.00 -0.00
Stochastic Oscillator 13.02 10.34

Price Performance

Historical Comparison
JOB
TPST

About JOB GEE Group Inc.

GEE Group Inc is a provider of specialized staffing solutions across the United States. The company's operating segment includes Industrial Staffing Services and Professional Staffing Services. It generates maximum revenue from the Professional Staffing Services segment. The company provides the following services, direct hire placement services, temporary professional services staffing in the fields of information technology, accounting, finance and office, engineering, and medical, and temporary light industrial staffing.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: